Ekaterina V. Kurbatova

Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis

Susan E. Dorman, Payam Nahid, Ekaterina V. Kurbatova et al. · New England Journal of Medicine · 2021 · 521 citations · Full text

Public Health Responses to COVID-19 Outbreaks on Cruise Ships — Worldwide, February–March 2020

Leah F. Moriarty, Mateusz M. Pluciński, Barbara J. Marston et al. · MMWR Morbidity and Mortality Weekly Report · 2020 · 426 citations · Full text

Virus Epidemiology, Covid-19 Outbreaks, Disease Outbreak +18

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Tracy Dalton, Peter Cegielski, Somsak Akksilp et al. · The Lancet · 2012 · 224 citations · Full text

Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Preventive Medicine +12

Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies

Ekaterina V. Kurbatova, J. Peter Cegielski, Christian Lienhardt et al. · The Lancet Respiratory Medicine · 2015 · 156 citations · Full text

Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis Prevention +8

Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects

Ekaterina V. Kurbatova, A. Taylor, Victoria M. Gammino et al. · Tuberculosis · 2012 · 152 citations · Full text

Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Disease Management +12